Production of Modified Autologous Conditioned Serum and Ex Vivo Assessment of Its Healing Potential in Murine Corneal Epithelium

This process presents an innovative blood derived product called mACS, which does not require any complex technical processing. It also accelerates wound healing to a greater extent than conventional autologous serum. In addition to providing a standardized preparation process, this technique can also reduce the cost of serum eyedrops, improving patient accessibility to a more affordable treatment option.

This technique may be applied in fields that require promoting wound or tissue regeneration, repair, and anti-inflammation. This technique will be a great advantage for difficult to heal wounds and chronic inflammatory diseases such as severe ocular surface diseases. To begin, inject 10 milliliters of the previously drawn human venous blood into each of the six vacutainer tubes.

Place the tubes in an incubator at 37 degrees Celsius for four hours and then centrifuge the tubes at 3, 500 G for 10 minutes at room temperature. Decap the tubes after placing them on the rack. After putting on sterile gloves, use a three milliliter syringe equipped with an 18 gauge needle to draw out the mACS from each tube.

Pull out the needle and attach a 0.22 micrometer filter. Connect the 23 gauge, 1.5 inch blood collection needle with the original three milliliter syringe to the outlet of the filter. Push the needle gently through the filter into the prepared sterile eyedrop bottles for immediate use, store the eyedrops at four degrees Celsius.

In the ex-vivo surface healing model, subjects treated with the mACS eyedrops displayed superior corneal healing relative to those treated with the autologous serum drops. At 16 hours, the corneal wounds of all groups healed slower than the one treated with 0.5%mACS. The murine cornea of the DMEM groups and autologous serum at 24 hours demonstrated comparable healing with mACSS at 32 hours except for the normal saline group.

All other groups showed close to full recovery. The most important step is to follow aseptic procedures during the process. Serum products are rich in nutrients so using contaminated products on the cornea can cause severe corneal ulcers.

This product can be used to assess the healing of wounds and the improvement of ocular surface disease symptoms. Analyzing the cytokine component and conducting larger randomized controlled trials of mACS are essential for further research.